HAYWARD,
Calif., May 9, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company, today announced that it will release first quarter
financial results before market open on Monday, May 16, 2022. AcelRx management will host
a live webcast and conference call at 8:30
a.m. Eastern Time (5:30 a.m. Pacific
Time) on May 16, 2022 to
discuss the financial results and provide an update on the
company's business.
The webcast is accessible by visiting the Investors page of the
company's website at www.acelrx.com and clicking on the webcast
link on the Investors home page. The webcast will be accompanied by
a slide presentation. A webcast replay will be available on
the AcelRx website for 90 days following the call by visiting the
Investor page of the company's website at www.acelrx.com.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers, or (412) 902-4204 for international
callers.
About AcelRx Pharmaceuticals,
Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings.
AcelRx's proprietary, non-invasive sublingual formulation
technology delivers sufentanil with consistent pharmacokinetic
profiles. The Company has one approved product in the U.S., DSUVIA®
(sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in
Europe, indicated for the
management of acute pain severe enough to require an opioid
analgesic for adult patients in certified medically supervised
healthcare settings, and several product candidates. The product
candidates include: Zalviso® (sufentanil sublingual tablet system,
SST system, 15 mcg), an investigational product in the U.S. being
developed as an innovatively designed patient-controlled analgesia
(PCA) system for reduction of moderate-to-severe acute pain in
medically supervised settings; two pre-filled, ready-to-use
syringes of ephedrine and phenylephrine licensed for the U.S. from
Aguettant; Niyad™, a regional anticoagulant for the extracorporeal
circuit; and LTX-608, for the potential treatment of COVID-19,
disseminated intravascular coagulation, acute respiratory distress
syndrome and acute pancreatitis. DZUVEO and Zalviso are both
approved products in Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-first-quarter-2022-financial-results-call-and-webcast-on-may-16-2022-301543167.html
SOURCE AcelRx Pharmaceuticals, Inc.